An individualized approach to the child with thyroid cancer

References

• Delellis A, Williams ED. Tumours of the thyroid and parathyroid. In: Pathology and Genetics of Tumours of Endocrine Organs. DeLellis RA, Lloyd RV, Heitz PU, Eng C (Eds). IARC Press, Lyon, France, 50–66 (2004).
   Google Scholar
• American Cancer Society. Cancer Facts & Figures 2009. American Cancer Society, Atlanta, GA, USA (2009).
   Google Scholar
• Horner MJ, Ries LAG, Krapcho M et al.SEER Cancer Statistics Review, 1975–2006. National Cancer Institute, Bethesda, MD, USA (2010).
   Google Scholar
• Hogan AR, Zhuge Y, Perez EA, Koniaris LG, Lew JI, Sola JE. Pediatric thyroid carcinoma: incidence and outcomes in 1753 patients. J. Surg. Res.156(1), 167–172 (2009).
   PubMedGoogle Scholar
• Demidchik YE, Demidchik EP, Reiners C et al. Comprehensive clinical assessment of 740 cases of surgically treated thyroid cancer in children of Belarus. Ann. Surg.243(4), 525–532 (2006).
   PubMedGoogle Scholar
• Borson-Chazot F, Causeret S, Lifante JC, Augros M, Berger N, Peix JL. Predictive factors for recurrence from a series of 74 children and adolescents with differentiated thyroid cancer. World J. Surg.28(11), 1088–1092 (2004).
   PubMed Web of Science ®Google Scholar
• Cooper DS, Doherty GM, Haugen BR et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid19(11), 1167–1214 (2009).
   PubMed Web of Science ®Google Scholar
• The NCCN Clinical Practice Guidelines in Oncology. Thyroid Carcinoma (Version 1.2010). National Comprehensive Cancer Network, Inc., Fort Washington, PA, USA (2010).
   Google Scholar
• American Association of Clinical Endocrinologists. American College of Endocrinology. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. Endocr. Pract.7(3), 202–220 (2001).
   PubMedGoogle Scholar
• Guidelines for the Management of Thyroid Cancer. Royal College of Physicians, London, UK (2007).
   Google Scholar
• Niedziela M. Pathogenesis, diagnosis and management of thyroid nodules in children. Endocr. Relat. Cancer13(2), 427–453 (2006).
   PubMedGoogle Scholar
• Gharib H, Papini E, Valcavi R et al. American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr. Pract.12(1), 63–102 (2006).
   PubMedGoogle Scholar
• Frankenthaler RA, Sellin RV, Cangir A, Goepfert H. Lymph node metastasis from papillary–follicular thyroid carcinoma in young patients. Am. J. Surg.160(4), 341–343 (1990).
   PubMed Web of Science ®Google Scholar
• Zimmerman D, Hay ID, Gough IR et al. Papillary thyroid carcinoma in children and adults: long-term follow-up of 1039 patients conservatively treated at one institution during three decades. Surgery104(6), 1157–1166 (1988).
   PubMed Web of Science ®Google Scholar
• Vassilopoulou-Sellin R, Klein MJ, Smith TH et al. Pulmonary metastases in children and young adults with differentiated thyroid cancer. Cancer71(4), 1348–1352 (1993).
   PubMed Web of Science ®Google Scholar
• Harness JK, Thompson NW, McLeod MK, Pasieka JL, Fukuuchi A. Differentiated thyroid carcinoma in children and adolescents. World J. Surg.16(4), 547–553; discussion 553–554 (1992).
   PubMedGoogle Scholar
• Welch Dinauer CA, Tuttle RM, Robie DK et al. Clinical features associated with metastasis and recurrence of differentiated thyroid cancer in children, adolescents and young adults. Clin. Endocrinol. (Oxf.)49(5), 619–628 (1998).
   PubMed Web of Science ®Google Scholar
• Wada N, Sugino K, Mimura T et al. Pediatric differentiated thyroid carcinoma in stage I: risk factor analysis for disease free survival. BMC Cancer9, 306 (2009).
   PubMedGoogle Scholar
• Schlumberger M, De Vathaire F, Travagli JP et al. Differentiated thyroid carcinoma in childhood: long term follow-up of 72 patients. J. Clin. Endocrinol. Metab.65(6), 1088–1094 (1987).
   PubMed Web of Science ®Google Scholar
• Bal CS, Kumar A, Chandra P, Dwivedi SN, Mukhopadhyaya S. Is chest x-ray or high-resolution computed tomography scan of the chest sufficient investigation to detect pulmonary metastasis in pediatric differentiated thyroid cancer? Thyroid14(3), 217–225 (2004).
   PubMedGoogle Scholar
• O’Gorman CS, Hamilton J, Rachmiel M, Gupta A, Ngan BY, Daneman D. Thyroid cancer in childhood: a retrospective review of childhood course. Thyroid20(4), 375–380 (2010).
   PubMedGoogle Scholar
• Hay ID, Gonzalez-Losada T, Reinalda MS, Honetschlager JA, Richards ML, Thompson GB. Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008. World J. Surg.34(6), 1192–1202 (2010).
   PubMedGoogle Scholar
• Vassilopoulou-Sellin R, Goepfert H, Raney B, Schultz PN. Differentiated thyroid cancer in children and adolescents: clinical outcome and mortality after long-term follow-up. Head Neck20(6), 549–555 (1998).
   PubMedGoogle Scholar
• Brink JS, van Heerden JA, McIver B et al. Papillary thyroid cancer with pulmonary metastases in children: long-term prognosis. Surgery128(6), 881–886; discussion 886–887 (2000).
   PubMedGoogle Scholar
• Durante C, Haddy N, Baudin E et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab.91(8), 2892–2899 (2006).
   PubMed Web of Science ®Google Scholar
• La Quaglia MP, Black T, Holcomb GW 3rd et al. Differentiated thyroid cancer: clinical characteristics, treatment, and outcome in patients under 21 years of age who present with distant metastases. A report from the Surgical Discipline Committee of the Children’s Cancer Group. J. Pediatr. Surg.35(6), 955–959; discussion 960 (2000).
   PubMed Web of Science ®Google Scholar
• Paediatric Endocrine Tumours. Spoudeas HA (Ed.). Novo Nordisk Ltd, West Sussex, UK (2005).
   Google Scholar
• Landau D, Vini L, A’Hern R, Harmer C. Thyroid cancer in children: the Royal Marsden Hospital experience. Eur. J. Cancer36(2), 214–220 (2000).
   PubMedGoogle Scholar
• Harach HR, Williams ED. Childhood thyroid cancer in England and Wales. Br. J. Cancer72(3), 777–783 (1995).
   PubMedGoogle Scholar
• Bal CS, Padhy AK, Kumar A. Clinical features of differentiated thyroid carcinoma in children and adolescents from a sub-Himalayan iodine-deficient endemic zone. Nucl. Med. Commun.22(8), 881–887 (2001).
   PubMedGoogle Scholar
• Lazar L, Lebenthal Y, Steinmetz A, Yackobovitch-Gavan M, Phillip M. Differentiated thyroid carcinoma in pediatric patients: comparison of presentation and course between pre-pubertal children and adolescents. J. Pediatr.154(5), 708–714 (2009).
   PubMed Web of Science ®Google Scholar
• Oertel JE, Klinck GH. Structural changes in the thyroid glands of healthy young men. Med. Ann. DC34, 75–77 (1965).
   PubMedGoogle Scholar
• Izquierdo R, Shankar R, Kort K, Khurana K. Ultrasound-guided fine-needle aspiration in the management of thyroid nodules in children and adolescents. Thyroid19(7), 703–705 (2009).
   PubMedGoogle Scholar
• Bargren AE, Meyer-Rochow GY, Sywak MS, Delbridge LW, Chen H, Sidhu SB. Diagnostic utility of fine-needle aspiration cytology in pediatric differentiated thyroid cancer. World J. Surg.34(6), 1254–1260 (2010).
   PubMedGoogle Scholar
• Yokozawa T, Fukata S, Kuma K et al. Thyroid cancer detected by ultrasound-guided fine-needle aspiration biopsy. World J. Surg.20(7), 848–853; discussion 853 (1996).
   PubMed Web of Science ®Google Scholar
• Stevens C, Lee JK, Sadatsafavi M, Blair GK. Pediatric thyroid fine-needle aspiration cytology: a meta-analysis. J. Pediatr. Surg.44(11), 2184–2191 (2009).
   PubMedGoogle Scholar
• Lyshchik A, Drozd V, Demidchik Y, Reiners C. Diagnosis of thyroid cancer in children: value of gray-scale and power doppler US. Radiology235(2), 604–613 (2005).
   PubMedGoogle Scholar
• Corrias A, Cassio A, Weber G et al. Thyroid nodules and cancer in children and adolescents affected by autoimmune thyroiditis. Arch. Pediatr. Adolesc. Med.162(6), 526–531 (2008).
   PubMedGoogle Scholar
• Ito Y, Higashiyama T, Takamura Y et al. Long-term follow-up for patients with papillary thyroid carcinoma treated as benign nodules. Anticancer Res.27(2), 1039–1043 (2007).
   PubMedGoogle Scholar
• Kouvaraki MA, Shapiro SE, Fornage BD et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery134(6), 946–954; discussion 954–945 (2003).
   PubMed Web of Science ®Google Scholar
• Shaha AR. TNM classification of thyroid carcinoma. World J. Surg.31(5), 879–887 (2007).
   PubMedGoogle Scholar
• Wada N, Sugino K, Mimura T et al. Treatment strategy of papillary thyroid carcinoma in children and adolescents: clinical significance of the initial nodal manifestation. Ann. Surg. Oncol.16(12), 3442–3449 (2009).
   PubMed Web of Science ®Google Scholar
• Welch Dinauer CA, Tuttle RM, Robie DK, McClellan DR, Francis GL. Extensive surgery improves recurrence-free survival for children and young patients with class I papillary thyroid carcinoma. J. Pediatr. Surg.34(12), 1799–1804 (1999).
   PubMed Web of Science ®Google Scholar
• Jarzab B, Handkiewicz Junak D, Wloch J et al. Multivariate analysis of prognostic factors for differentiated thyroid carcinoma in children. Eur. J. Nucl. Med.27(7), 833–841 (2000).
   PubMedGoogle Scholar
• Bilimoria KY, Bentrem DJ, Ko CY et al. Extent of surgery affects survival for papillary thyroid cancer. Ann. Surg.246(3), 375–381; discussion 381–374 (2007).
   PubMed Web of Science ®Google Scholar
• Hung W, Sarlis NJ. Current controversies in the management of pediatric patients with well-differentiated nonmedullary thyroid cancer: a review. Thyroid12(8), 683–702 (2002).
   PubMedGoogle Scholar
• Thompson GB, Hay ID. Current strategies for surgical management and adjuvant treatment of childhood papillary thyroid carcinoma. World J. Surg.28(12), 1187–1198 (2004).
   PubMed Web of Science ®Google Scholar
• Rachmiel M, Charron M, Gupta A et al. Evidence-based review of treatment and follow up of pediatric patients with differentiated thyroid carcinoma. J. Pediatr. Endocrinol. Metab.19(12), 1377–1393 (2006).
   PubMedGoogle Scholar
• Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery114(6), 1050–1057; discussion 1057–1058 (1993).
   PubMed Web of Science ®Google Scholar
• Shah MD, Hall FT, Eski SJ, Witterick IJ, Walfish PG, Freeman JL. Clinical course of thyroid carcinoma after neck dissection. Laryngoscope113(12), 2102–2107 (2003).
   PubMedGoogle Scholar
• Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J. Clin. Endocrinol. Metab.87(4), 1499–1501 (2002).
   PubMed Web of Science ®Google Scholar
• Demidchik Iu E, Kontratovich VA. [Repeat surgery for recurrent thyroid cancer in children]. Vopr. Onkol.49(3), 366–369 (2003).
   PubMedGoogle Scholar
• Newman KD, Black T, Heller G et al. Differentiated thyroid cancer: determinants of disease progression in patients <21 years of age at diagnosis: a report from the Surgical Discipline Committee of the Children’s Cancer Group. Ann. Surg.227(4), 533–541 (1998).
   PubMedGoogle Scholar
• Musacchio MJ, Kim AW, Vijungco JD, Prinz RA. Greater local recurrence occurs with ‘berry picking’ than neck dissection in thyroid cancer. Am. Surg.69(3), 191–196; discussion 196–197 (2003).
   PubMed Web of Science ®Google Scholar
• Sosa JA, Tuggle CT, Wang TS et al. Clinical and economic outcomes of thyroid and parathyroid surgery in children. J. Clin. Endocrinol. Metab.93(8), 3058–3065 (2008).
   PubMed Web of Science ®Google Scholar
• Gimm O, Rath FW, Dralle H. Pattern of lymph node metastases in papillary thyroid carcinoma. Br. J. Surg.85(2), 252–254 (1998).
   PubMed Web of Science ®Google Scholar
• Salter KD, Andersen PE, Cohen JI et al. Central nodal metastases in papillary thyroid carcinoma based on tumor histologic type and focality. Arch. Otolaryngol. Head Neck Surg.136(7), 692–696 (2010).
   PubMedGoogle Scholar
• Vergez S, Sarini J, Percodani J, Serrano E, Caron P. Lymph node management in clinically node-negative patients with papillary thyroid carcinoma. Eur. J. Surg. Oncol.36(8), 777–782 (2010).
   PubMedGoogle Scholar
• Sywak M, Cornford L, Roach P, Stalberg P, Sidhu S, Delbridge L. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery140(6), 1000–1005; discussion 1005–1007 (2006).
   PubMed Web of Science ®Google Scholar
• Grubbs EG, Rich TA, Li G et al. Recent advances in thyroid cancer. Curr. Probl. Surg.45(3), 156–250 (2008).
   PubMed Web of Science ®Google Scholar
• Shen WT, Ogawa L, Ruan D, Suh I, Duh QY, Clark OH. Central neck lymph node dissection for papillary thyroid cancer: the reliability of surgeon judgment in predicting which patients will benefit. Surgery148(2), 398–403 (2010).
   PubMedGoogle Scholar
• Shindo M, Stern A. Total thyroidectomy with and without selective central compartment dissection: a comparison of complication rates. Arch. Otolaryngol. Head Neck Surg.136(6), 584–587 (2010).
   PubMedGoogle Scholar
• White ML, Gauger PG, Doherty GM. Central lymph node dissection in differentiated thyroid cancer. World J. Surg.31(5), 895–904 (2007).
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am. J. Med.97(5), 418–428 (1994).
   PubMed Web of Science ®Google Scholar
• Jonklaas J, Sarlis NJ, Litofsky D et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid16(12), 1229–1242 (2006).
   PubMed Web of Science ®Google Scholar
• Sawka AM, Brierley JD, Tsang RW et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol. Metab. Clin. North Am.37(2), 457–480 (2008).
   PubMed Web of Science ®Google Scholar
• Clayman GL, Shellenberger TD, Ginsberg LE et al. Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma. Head Neck31(9), 1152–1163 (2009).
   PubMedGoogle Scholar
• Chow S, Law S, Mendenhall W et al. Differentiated thyroid carcinoma in childhood and adolescence – clinical course and role of radioiodine. Pediatr. Blood Cancer42, 176–183 (2004).
   PubMedGoogle Scholar
• Rubino C, de Vathaire F, Dottorini ME et al. Second primary malignancies in thyroid cancer patients. Br. J. Cancer89(9), 1638–1644 (2003).
   PubMed Web of Science ®Google Scholar
• Sawka AM, Lakra DC, Lea J et al. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin. Endocrinol. (Oxf.)69, 479–490 (2008).
   PubMedGoogle Scholar
• Sawka AM, Lea J, Alshehri B et al. A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors. Clin. Endocrinol. (Oxf.)68(4), 610–617 (2008).
   PubMed Web of Science ®Google Scholar
• Meier DA, Brill DR, Becker DV et al. Procedure guideline for therapy of thyroid disease with (131)iodine. J. Nucl. Med.43(6), 856–861 (2002).
   PubMedGoogle Scholar
• Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J. Clin. Endocrinol. Metab.93(2), 504–515 (2008).
   PubMed Web of Science ®Google Scholar
• Dottorini ME, Vignati A, Mazzucchelli L, Lomuscio G, Colombo L. Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients. J. Nucl. Med.38(5), 669–675 (1997).
   PubMedGoogle Scholar
• Sawka AM, Thabane L, Parlea L et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid19(5), 451–457 (2009).
   PubMed Web of Science ®Google Scholar
• Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid13(3), 265–271 (2003).
   PubMed Web of Science ®Google Scholar
• Bhattacharyya N, Chien W. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma. Ann. Otol. Rhinol. Laryngol.115(8), 607–610 (2006).
   PubMedGoogle Scholar
• Dinauer C, Francis GL. Thyroid cancer in children. Endocrinol. Metab. Clin. North Am.36(3), 779–806, vii (2007).
   PubMedGoogle Scholar
• Kuijt WJ, Huang SA. Children with differentiated thyroid cancer achieve adequate hyperthyrotropinemia within 14 days of levothyroxine withdrawal. J. Clin. Endocrinol. Metab.90(11), 6123–6125 (2005).
   PubMedGoogle Scholar
• Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol.154(6), 787–803 (2006).
   PubMed Web of Science ®Google Scholar
• Tuttle RM, Brokhin M, Omry G et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J. Nucl. Med.49(5), 764–770 (2008).
   PubMed Web of Science ®Google Scholar
• Hanscheid H, Lassmann M, Luster M et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J. Nucl. Med.47(4), 648–654 (2006).
   PubMed Web of Science ®Google Scholar
• Lau WF, Zacharin MR, Waters K, Wheeler G, Johnston V, Hicks RJ. Management of paediatric thyroid carcinoma: recent experience with recombinant human thyroid stimulating hormone in preparation for radioiodine therapy. Intern. Med. J.36(9), 564–570 (2006).
   PubMedGoogle Scholar
• Luster M, Handkiewicz-Junak D, Grossi A et al. Recombinant thyrotropin use in children and adolescents with differentiated thyroid cancer: a multicenter retrospective study. J. Clin. Endocrinol. Metab.94(10), 3948–3953 (2009).
   PubMedGoogle Scholar
• Hung W, Sarlis NJ. Current controversies in the management of pediatric patients with well- differentiated nonmedullary thyroid cancer: a review. Thyroid12(8), 683–702 (2002).
   PubMedGoogle Scholar
• Leboulleux S, Baudin E, Hartl DW, Travagli JP, Schlumberger M. Follicular cell-derived thyroid cancer in children. Horm. Res.63(3), 145–151 (2005).
   PubMedGoogle Scholar
• Reynolds JC. Comparison of I-131 absorbed radiation doses in children and adults: a tool for estimating therapeutic I-131 doses in children. In: Treatment of Thyroid Cancer in Childhood. Robbins JM (Ed.). NIDDK, National Institutes of Health, Bethesda, MD, USA, 127–135 (1992).
   Google Scholar
• Tuttle RM, Leboeuf R, Robbins RJ et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J. Nucl. Med.47(10), 1587–1591 (2006).
   PubMed Web of Science ®Google Scholar
• Lassmann M, Reiners C, Luster M. Dosimetry and thyroid cancer – the individual dosage of radioiodine. Endocr. Relat. Cancer17(3), R161–R172 (2010).
   PubMed Web of Science ®Google Scholar
• Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll R, Gulec S. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J. Nucl. Med.44(3), 451–456 (2003).
   PubMed Web of Science ®Google Scholar
• Maxon HR. The role of radioiodine in the treatment of childhood thyroid cancer – a dosimetric approach. In: Treatment of Thyroid Cancer in Childhood. Robbins JM (Ed.). NIDDK, National Institutes of Health, Bethesda, MD, USA, 109–126 (1992).
   Google Scholar
• Maxon HR, Thomas SR, Hertzberg VS et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N. Engl. J. Med.309(16), 937–941 (1983).
   PubMed Web of Science ®Google Scholar
• Reynolds JC, Robbins J. The changing role of radioiodine in the management of differentiated thyroid cancer. Semin. Nucl. Med.27(2), 152–164 (1997).
   PubMed Web of Science ®Google Scholar
• Tuttle RM, Grewal RK, Larson SM. Radioactive iodine therapy in poorly differentiated thyroid cancer. Nat. Clin. Pract. Oncol.4(11), 665–668 (2007).
   PubMedGoogle Scholar
• Arora N, Turbendian HK, Kato MA, Moo TA, Zarnegar R, Fahey TJ 3rd. Papillary thyroid carcinoma and microcarcinoma: is there a need to distinguish the two? Thyroid19(5), 473–477 (2009).
   PubMedGoogle Scholar
• Hay ID, Hutchinson ME, Gonzalez-Losada T et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery144(6), 980–987; discussion 987–988 (2008).
   PubMed Web of Science ®Google Scholar
• Noguchi S, Yamashita H, Uchino S, Watanabe S. Papillary microcarcinoma. World J. Surg.32(5), 747–753 (2008).
   PubMedGoogle Scholar
• Hay ID, Grant CS, van Heerden JA, Goellner JR, Ebersold JR, Bergstralh EJ. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery112(6), 1139–1146; discussion 1146–1137 (1992).
   PubMed Web of Science ®Google Scholar
• Lo CY, Chan WF, Lang BH, Lam KY, Wan KY. Papillary microcarcinoma: is there any difference between clinically overt and occult tumors? World J. Surg.30(5), 759–766 (2006).
   PubMedGoogle Scholar
• Marcy PY, Thariat J, Peyrottes I et al. Fulminant lethal spread of occult papillary microcarcinoma of the thyroid. Thyroid20(4), 445–448 (2010).
   PubMedGoogle Scholar
• Taylor T, Specker B, Robbins J et al. Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann. Intern. Med.129(8), 622–627 (1998).
   PubMedGoogle Scholar
• Asari R, Koperek O, Scheuba C et al. Follicular thyroid carcinoma in an iodine-replete endemic goiter region: a prospectively collected, retrospectively analyzed clinical trial. Ann. Surg.249(6), 1023–1031 (2009).
   PubMed Web of Science ®Google Scholar
• Zou CC, Zhao ZY, Liang L. Childhood minimally invasive follicular carcinoma: clinical features and immunohistochemistry analysis. J. Paediatr. Child Health46(4), 166–170 (2010).
   PubMedGoogle Scholar
• Biondi B, Filetti S, Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat. Clin. Pract. Endocrinol. Metab.1(1), 32–40 (2005).
   PubMedGoogle Scholar
• Pacini F, Molinaro E, Castagna MG et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab.88(8), 3668–3673 (2003).
   PubMed Web of Science ®Google Scholar
• Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J. Clin. Endocrinol. Metab.87(7), 3242–3247 (2002).
   PubMed Web of Science ®Google Scholar
• Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J. Clin. Endocrinol. Metab.85(1), 175–178 (2000).
   PubMed Web of Science ®Google Scholar
• Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J. Clin. Endocrinol. Metab.90(9), 5047–5057 (2005).
   PubMed Web of Science ®Google Scholar
• Pacini F, Agate L, Elisei R et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic 131I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J. Clin. Endocrinol. Metab.86(9), 4092–4097 (2001).
   PubMed Web of Science ®Google Scholar
• Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J. Clin. Endocrinol. Metab.80(5), 1488–1492 (1995).
   PubMed Web of Science ®Google Scholar
• Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J. Clin. Endocrinol. Metab.88(3), 1107–1111 (2003).
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL, Robbins RJ, Spencer CA et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J. Clin. Endocrinol. Metab.88(4), 1433–1441 (2003).
   PubMed Web of Science ®Google Scholar
• Bauer AJ, Tuttle RM, Francis G. Thyroid nodules and thyroid carcinoma in children. In: Pediatric Endocrinology: Mechanisms, Manifestations, and Management. Pescovitz O, Eugster E (Eds). Lippincott, Inc., Philadelphia, PA, USA (2004).
   Google Scholar
• Antonelli A, Miccoli P, Fallahi P et al. Role of neck ultrasonography in the follow-up of children operated on for thyroid papillary cancer. Thyroid13(5), 479–484 (2003).
   PubMed Web of Science ®Google Scholar
• Samuel AM, Rajashekharrao B, Shah DH. Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. J. Nucl. Med.39(9), 1531–1536 (1998).
   PubMedGoogle Scholar
• Demidchik YE, Saenko VA, Yamashita S. Childhood thyroid cancer in Belarus, Russia, and Ukraine after Chernobyl and at present. Arq. Bras. Endocrinol. Metabol.51(5), 748–762 (2007).
   PubMedGoogle Scholar
• LaQuaglia M, Black T, Holcomb G et al. Differentiated thyroid cancer: clinical characteristics, treatment, and outcome in patients under 21 years of age who present with distant metastases. A report from the Surgical Discipline Committee of the Children’s Cancer Group. J. Pediatr. Surg.35(6), 955–959 (2000).
   PubMedGoogle Scholar
• Spencer CA, Takeuchi M, Kazarosyan M et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab.83(4), 1121–1127 (1998).
   PubMed Web of Science ®Google Scholar
• Chiovato L, Latrofa F, Braverman LE et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann. Intern. Med.139(5 Pt 1), 346–351 (2003).
   PubMed Web of Science ®Google Scholar
• Harach HR, Williams ED. Childhood thyroid cancer in England and Wales. Br. J. Cancer72(3), 777–783 (1995).
   PubMedGoogle Scholar
• Niedziela M, Maceluch J, Korman E. Galectin-3 is not an universal marker of malignancy in thyroid nodular disease in children and adolescents. J. Clin. Endocrinol. Metab.87(9), 4411–4415 (2002).
   PubMedGoogle Scholar
• Polyzos SA, Kita M, Efstathiadou Z et al. Serum thyrotropin concentration as a biochemical predictor of thyroid malignancy in patients presenting with thyroid nodules. J. Cancer Res. Clin. Oncol.134(9), 953–960 (2008).
   PubMed Web of Science ®Google Scholar
• Hoperia V, Larin A, Jensen K, Bauer AJ, Vasko V. Thyroid fine needle aspiration biopsies in children: study of cytological–histological correlation and immunostaining with anti-thyroid peroxidase monoclonal antibodies (MoAb47). Int. J. Pediatr. Endocrinol. (2010) (In Press).
   PubMedGoogle Scholar
• Nikiforov YE, Steward DL, Robinson-Smith TM et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J. Clin. Endocrinol. Metab.94(6), 2092–2098 (2009).
   PubMed Web of Science ®Google Scholar
• Sobrinho-Simoes M, Maximo V, Rocha AS et al. Intragenic mutations in thyroid cancer. Endocrinol. Metab. Clin. North Am.37(2), 333–362, viii (2008).
   PubMed Web of Science ®Google Scholar
• Xing M, Westra WH, Tufano RP et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J. Clin. Endocrinol. Metab.90(12), 6373–6379 (2005).
   PubMed Web of Science ®Google Scholar
• Penko K, Livezey J, Fenton C et al. BRAF mutations are uncommon in papillary thyroid cancer of young patients. Thyroid15(4), 320–325 (2005).
   PubMedGoogle Scholar
• Yamashita S, Saenko V. Mechanisms of disease: molecular genetics of childhood thyroid cancers. Nat. Clin. Pract. Endocrinol. Metab.3(5), 422–429 (2007).
   PubMedGoogle Scholar
• Keefe SM, Cohen MA, Brose MS. Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications. Clin. Cancer Res.16(3), 778–783 (2010).
   PubMed Web of Science ®Google Scholar
• Sherman SI. Targeted therapy of thyroid cancer. Biochem. Pharmacol.80(5), 592–601 (2010).
   PubMed Web of Science ®Google Scholar
• Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J. Clin. Endocrinol. Metab.94(5), 1493–1499 (2009).
   PubMed Web of Science ®Google Scholar
• Waguespack SG, Sherman SI, Williams MD, Clayman GL, Herzog CE. The successful use of sorafenib to treat pediatric papillary thyroid carcinoma. Thyroid19(4), 407–412 (2009).
   PubMed Web of Science ®Google Scholar
• Woyach J, Shah M. New therapeutic advances in the management of progressive thyroid cancer. Endocr. Relat. Cancer16(3), 715–731 (2009).
   PubMedGoogle Scholar